Replies to post #158915 on Biotech Values

[DewDiligence]

More info on Tecfidera approval…

FDA label:
http://t.co/lpJBJWgFts

BIIB’s PR:
http://finance.yahoo.com/news/biogen-idec-tecfidera-dimethyl-fumarate-201000820.html

[jbog]

With Biogen pricing Tecfidera ($55k/yr) right in the middle of Gilenya ($60K/yr) and Aubagio ($48.0k/yr.

After a year or so if Tecfidera's side effect profile is within expectations it'll take the dominant position in MS care.

The injectables, Copaxone, Rebif and Avonex will start to wither away once the safety parameters are met.